The Beatrice Hunter Cancer Research Institute logo
  • Dr. Tallal Younis, MBBCh. FACP. FRCP (UK)

Appointments:

Medical Oncologist, CDHA - QE II Health Sciences Centre. Associate Professor of Medicine, Dalhousie University. Clinical Research Scholar, Dalhousie University. National Cancer Institute of Canada (NCIC) – Working Group on Economic Analysis (WGEA), Member. Pan Canadian Oncology Drug Review (pCODR) – Expert Review Committee (pERC), Member.

Affiliations:

CDHA, QE II Health Sciences Centre; Dalhousie University, Department of Medicine

Research Interests:

Breast Cancer, Health Services and Outcomes Research, Health Economics, Pharmaco Economics, Comparative Effectiveness Research, Clinical Trials

The optimal choices of systemic therapy in Breast Cancer

The overall goal of my research is to optimize the systemic therapy in early stage breast cancer through health services and health economics research. The specific aims of my ongoing and/or planned projects involve; 1) identifying the economically-preferred treatments that maximize overall health benefits within budget constraints; 2) assessing the current utilization rates of systemic treatments and/or adjunct tests, and the predictors of higher versus lower utilization; and 3) examining the current versus acceptable wait times, and predictors of longer wait times, to receive systemic therapies.

Membership Status:

Dr. Younis is a BHCRI Senior Scientist and has been a BHCRI Seminar Series presenter.

Phone:

(902) 473-6054

Email:

tallal.younis@cdha.nshealth.ca

Address:

Queen Elizabeth II Health Sciences Centre. 1276 South Park Street. 454 Bethune Building, Halifax, NS, Canada, B3H2Y9

Publications:

Younis T, Rayson D, Skedgel C. The Cost Utility of Adjuvant Chemotherapy with Docetaxel and Cyclophosphamide compared to Adriamycin and Cyclophosphamide in Breast Cancer. [Current Oncology 2011: In Press]

Younis T and Skedgel C. Adjuvant Trastuzumab in Breast Cancer: Uncertainty in Clinical and Economic Evidence Following Early Stopping of HERA trial !  (Editorial Commentary) [Pharmacoeconomics 2011 May; 29(5): 361-365]

Rayson D, Payne JI, Abdolell M, Barnes PJ, MacIntosh R, Foley T, Younis T, Burns A, Caines J. Clinical-pathologic characteristics and outcomes of true interval compared to screen-detected breast cancer among participants in a Canadian breast screening program: A nested case-control study. [Clinical Breast Cancer 2011 Mar; 11(1): 27-32]

Chiong Y, Mulroy L, Fleetwood I, Younis T. Isolated metastasis to the cerebellopontine angle (CPA). [Can J Surg 2009 Oct; 52(5): E213-214]

Younis T, Dakin-Hache KA, Rayson D, Dewar R, Gray S, Barnes PJ. Survivin and COX-2 expression in male breast cancer. [Breast. 2009 Aug; 18(4): 228-232]

Skedgel C, Rayson D, Younis T. The Cost-utility of adjuvant trastuzumab in women with Her2/neu-positive breast cancer: Probabilistic Modeling within a Net-Benefits Framework. [Value Health. 2009 March (Epub ahead of Print)]

Younis T, Milch R, Abul-Khoudoud N, Lawrence D, Mirand A, Levine A. Length of survival in hospice for cancer patients referred from a comprehensive cancer center. [Am J Hosp Palliat Care. 2009 Aug-Sep; 26(4): 281-287]

Au H-J, Golmohammadi K, Younis T, Verma S, Chia S, Fassbender K, Jacobs P. Cost-Effectiveness Analysis of Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) for Node-Positive Breast Cancer:  Modeling the Downstream Effects. [Breast Cancer Res Treat. 2009 Apr; 114(3): 579-587]

Younis T, Al-Fayea T, Virik K, Morzycki W, Saint-Jacques N. Uptake of adjuvant chemotherapy in early-stage non small cell lung cancer (NSCLC). [J Thorac Oncol. 2008 Nov; 3(11): 1272-8]

Younis T and Skedgel C. Is trastuzumab a cost-effective treatment for breast cancer? [Expert Rev Pharmacoeconomics Outcomes Res. 2008 Oct; 8(5): 433-42]

Site by: Spectacle Group